Inhibikase Therapeutics (IKT) Other financing activities (2024)
Inhibikase Therapeutics (IKT) reported Other financing activities of -$30608.0 for Q1 2024.
Inhibikase Therapeutics (IKT) Other financing activities (2024) Analysis & Trends
Inhibikase Therapeutics (IKT) has 1 years of Other financing activities data on file, last reported at -$30608.0 in Q1 2024.
- Other financing activities for Q1 2024 came in at -$30608.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was -$30608.0 (changed N/A YoY), and the FY2023 annual result was -$138556.0, changed N/A from the prior year.
- Other financing activities was little changed at -$30608.0 in Q1 2024 per IKT's latest filing.
- Over five years, Other financing activities peaked at -$30608.0 in Q1 2024 and troughed at -$30608.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -30,608.00 |
| Mar 31, 2024 | -30,608.00 |